SynthesisHypertension research : official journal of the Japanese Society of Hypertension2019
Systematic review of the clinical outcomes of mineralocorticoid receptor antagonist treatment versus adrenalectomy in patients with primary aldosteronism.
Synthesis in Hypertension research : official journal of the Japanese Society of Hypertension, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- A systematic review to compare adrenalectomy and mineralocorticoid receptor antagonists in patients with unilateral primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Pooled it
- Time to Benefit of Surgery vs Targeted Medical Therapy for Patients With Primary Aldosteronism: A Meta-analysis.The Journal of clinical endocrinology and metabolism · 2024Pooled it
- The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019).Hypertension research : official journal of the Japanese Society of Hypertension · 2019Guideline
- Metabolic and body composition shifts after adrenalectomy in unilateral primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2026Article
- The amount of sodium intake may affect the susceptibility to treatment with mineralocorticoid receptor antagonists in patients with primary aldosteronism.Clinical and experimental nephrology · 2026Article
- Things We Do for No Reason™: Failing to consider primary aldosteronism in the initial evaluation of hypertension, hypertensive urgency, and hypertensive emergency.Journal of hospital medicine · 2025Article
- Multimodality Imaging in Aldosterone-Induced Cardiomyopathy: Early Detection and Prognostic Implications.Diagnostics (Basel, Switzerland) · 2025Review
- Short-term longitudinal clinical, biochemical, and quality of life outcomes of medical or surgical therapy in unilateral primary aldosteronism.Frontiers in endocrinology · 2025Article
- Bilateral adrenal artery embolization for the treatment of idiopathic hyperaldosteronism: A proof-of-principle single center study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Diagnosis and management of adrenal incidentaloma: use of clinical judgment and evidence in dialog with the patient.Surgery today · 2024Review
- Targeted Treatment Reverses Increased Left Cardiac Work in Unilateral vs. Bilateral Primary Aldosteronism.American journal of hypertension · 2024Article
- Rationality and implication of catheter-based adrenal ablation for bilateral primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Addition of Sacubitril/Valsartan to Mineralocorticoid Receptor Antagonist Therapy in Primary Aldosteronism: Effects on Plasma Aldosterone Concentration and Plasma Renin Activity.Journal of clinical medicine research · 2024Article
- Shifting paradigms in primary aldosteronism: reconsideration of screening strategy via integrating pathophysiological insights.Frontiers in endocrinology · 2024Review
- Article
- Primary Aldosteronism and the Role of Mineralocorticoid Receptor Antagonists for the Heart and Kidneys.Annual review of medicine · 2023Review
- Imaging or Adrenal Vein Sampling Approach in Primary Aldosteronism? A Patient-Based Approach.Tomography (Ann Arbor, Mich.) · 2022Review
- Article
- Case report: Percutaneous adrenal arterial embolization cures resistant hypertension.Frontiers in cardiovascular medicine · 2022Article
- Exosomes and exosomal cargo in urinary extracellular vesicles: novel potential biomarkers for mineralocorticoid-receptor-associated hypertension.Hypertension research : official journal of the Japanese Society of Hypertension · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is the most common cause of secondary hypertension. The aim of this study was to review the clinical outcomes after mineralocorticoid receptor (MR) antagonist treatment versus adrenalectomy treatment in patients with PA. Relevant medical literature from PubMed, the Cochrane Library, and the ICHUSHI database from 1985 to August 2017 was reviewed. Data extraction was performed independently by three authors. The incidence of cerebrovascular or cardiovascular disease, the improvement of left ventricular hypertrophy or hypokalemia, the severity of hypertension, the incidence of renal dysfunction, and the reduction in the number of oral antihypertensive agents were set as the clinical outcomes. Of the 302 articles selected, 16 were included in the final analysis. Regarding the two therapeutic strategies, no difference in the reduced incidence of cerebrovascular or cardiovascular disease, the prevalence of left ventricular hypertrophy or hypokalemia, or the severity of hypertension, as well as an increase in the incidence of renal dysfunction was observed. Regarding the decrease in the number of oral antihypertensive agents, more agents were reduced in patients who underwent adrenalectomy. Available evidence indicated that the clinical outcomes were not different in PA patients treated with MR antagonist or adrenalectomy, except for a reduction in the number of antihypertensive agents.
Indexed as
Identifiers
30948836What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.